Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

BACKGROUND: The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike protein of SARS-CoV-2. METHODS: We did a phase 1/2,...

Descripción completa

Detalles Bibliográficos
Autores principales: Folegatti, Pedro M, Ewer, Katie J, Aley, Parvinder K, Angus, Brian, Becker, Stephan, Belij-Rammerstorfer, Sandra, Bellamy, Duncan, Bibi, Sagida, Bittaye, Mustapha, Clutterbuck, Elizabeth A, Dold, Christina, Faust, Saul N, Finn, Adam, Flaxman, Amy L, Hallis, Bassam, Heath, Paul, Jenkin, Daniel, Lazarus, Rajeka, Makinson, Rebecca, Minassian, Angela M, Pollock, Katrina M, Ramasamy, Maheshi, Robinson, Hannah, Snape, Matthew, Tarrant, Richard, Voysey, Merryn, Green, Catherine, Douglas, Alexander D, Hill, Adrian V S, Lambe, Teresa, Gilbert, Sarah C, Pollard, Andrew J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445431/
https://www.ncbi.nlm.nih.gov/pubmed/32702298
http://dx.doi.org/10.1016/S0140-6736(20)31604-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445431/
https://www.ncbi.nlm.nih.gov/pubmed/32702298
http://dx.doi.org/10.1016/S0140-6736(20)31604-4

Ejemplares similares